Trial Outcomes & Findings for A Study of LY2090314 in Patients With Advanced or Metastatic Cancer (NCT NCT01287520)

Last Updated: 2019-02-25

Results Overview

Recommended Phase 2 MTD was determined, when a dose limiting toxicity (DLT) occurred in 1 of 3 participants, the cohort was to be expanded to 6 participants. If a DLT occurred in 2 or more participants, accrual to the cohort was stopped, as the MTD was exceeded. A DLT was defined as an adverse event (AE) occurring in Cycle 1 (28 days) that was possibly related to study drug and met 1 of the following criteria: According to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0, ≥Grade 3 nonhematologic toxicity (except for nausea/vomiting without maximal symptomatic/prophylactic treatment) possibly or likely related to the study medication;CTCAE Grade 4 hematological toxicity of \>5 days duration; Febrile neutropenia; CTCAE Grade 4 thrombocytopenia; CTCAE ≥Grade 2 thrombocytopenia plus bleeding; CTCAE ≥Grade 3 prolonged QTc interval.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

41 participants

Primary outcome timeframe

Baseline up to Day 28 (Cycle 1)

Results posted on

2019-02-25

Participant Flow

The reasons for discontinuation listed in the participant flow are the reasons the participant discontinued treatment and a participant was considered to have "completed" the trial if they discontinued treatment due to progressive disease or an adverse event.

Participant milestones

Participant milestones
Measure	LY 10/Carb 5/Pem 500 (Cohort 1) * Cycle 1 Day 1 of 28-day cycle: 10 milligrams (mg) LY2090314 (LY) administered by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 milligrams per meter squared (mg/m\^2) pemetrexed (Pem) administered by intravenous infusion followed by Area Under the Time Curve (AUC) 5 milligrams per milliliter times minutes (mg/mL \* min) carboplatin (Carb) administered by intravenous infusion. * Cycle 2 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem administered by intravenous infusion followed by AUC 5 mg/mL \* min Carb administered by intravenous infusion followed by 10 mg LY2090314 administered by intravenous infusion.	LY 10/Carb 6/Pem 500 (Cohort 2) * Cycle 1 Day 1 of 28-day cycle: 10 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 10 mg LY2090314 by intravenous infusion.	LY 20/Carb 6/Pem 500 (Cohort 3) * Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.	LY 40/Carb 6/Pem 500 (Cohort 4) * Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 and beyond: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.	LY 80/Carb 6/Pem 500 (Cohort 5) * Cycle 1 Day 1 of 28 -ay cycle: 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up and beyond: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion	LY 120/Carb 6/Pem 500 -(Cohort 6) * Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.	LY 80/Carb 6/Pem 500 + R50 (Cohort 7) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine (R50) intravenous, 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem IV infusion. * Cycle 3 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by IV infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 40/Carb 6/Pem 500 + R50 (Cohort 9) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine IV pretreatment and 40 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.
Overall Study STARTED	3	7	5	7	3	4	2	5	5
Overall Study COMPLETED	0	0	0	0	0	0	0	0	0
Overall Study NOT COMPLETED	3	7	5	7	3	4	2	5	5

Reasons for withdrawal

Reasons for withdrawal
Measure	LY 10/Carb 5/Pem 500 (Cohort 1) * Cycle 1 Day 1 of 28-day cycle: 10 milligrams (mg) LY2090314 (LY) administered by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 milligrams per meter squared (mg/m\^2) pemetrexed (Pem) administered by intravenous infusion followed by Area Under the Time Curve (AUC) 5 milligrams per milliliter times minutes (mg/mL \* min) carboplatin (Carb) administered by intravenous infusion. * Cycle 2 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem administered by intravenous infusion followed by AUC 5 mg/mL \* min Carb administered by intravenous infusion followed by 10 mg LY2090314 administered by intravenous infusion.	LY 10/Carb 6/Pem 500 (Cohort 2) * Cycle 1 Day 1 of 28-day cycle: 10 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 10 mg LY2090314 by intravenous infusion.	LY 20/Carb 6/Pem 500 (Cohort 3) * Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.	LY 40/Carb 6/Pem 500 (Cohort 4) * Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 and beyond: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.	LY 80/Carb 6/Pem 500 (Cohort 5) * Cycle 1 Day 1 of 28 -ay cycle: 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up and beyond: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion	LY 120/Carb 6/Pem 500 -(Cohort 6) * Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.	LY 80/Carb 6/Pem 500 + R50 (Cohort 7) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine (R50) intravenous, 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem IV infusion. * Cycle 3 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by IV infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 40/Carb 6/Pem 500 + R50 (Cohort 9) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 and beyond: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine IV pretreatment and 40 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.
Overall Study Adverse Event	2	2	2	1	1	2	0	2	0
Overall Study Physician Decision	1	1	2	0	1	1	0	1	0
Overall Study Progressive disease	0	4	1	6	1	0	2	2	4
Overall Study Withdrawal by Subject	0	0	0	0	0	1	0	0	1

Baseline Characteristics

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	LY 10/Carb 5/Pem 500 (Cohort 1) n=3 Participants * Cycle 1 Day 1 of 28-day cycle: 10 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 mg/mL \* min Carb by intravenous infusion followed by 10 mg LY2090314 by intravenous infusion.	LY 10/Carb 6/Pem 500 (Cohort 2) n=7 Participants * Cycle 1 Day 1 of 28-day cycle: 10 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 10 mg LY2090314 by intravenous infusion.	LY 20/Carb 6/Pem 500 (Cohort 3) n=5 Participants * Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.	LY 40/Carb 6/Pem 500 (Cohort 4) n=7 Participants * Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.	LY 80/Carb 6/Pem 500 (Cohort 5) n=3 Participants * Cycle 1 Day 1 of 28-day cycle: 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion.	LY 120/Carb 6/Pem 500 (Cohort 6) n=4 Participants * Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.	LY 80/Carb 6/Pem 500 + R50 (Cohort 7) n=2 Participants * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) n=5 Participants * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 40/Carb 6/Pem 500 + R50 (Cohort 9) n=5 Participants * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	Total n=41 Participants Total of all reporting groups
Age, Continuous	55.81 years STANDARD_DEVIATION 11.88 • n=5 Participants	55.27 years STANDARD_DEVIATION 9.19 • n=7 Participants	59.31 years STANDARD_DEVIATION 5.62 • n=5 Participants	58.32 years STANDARD_DEVIATION 8.95 • n=4 Participants	57.35 years STANDARD_DEVIATION 7.59 • n=21 Participants	56.73 years STANDARD_DEVIATION 7.52 • n=8 Participants	55.39 years STANDARD_DEVIATION 9.86 • n=8 Participants	58.78 years STANDARD_DEVIATION 9.06 • n=24 Participants	61.35 years STANDARD_DEVIATION 4.41 • n=42 Participants	57.79 years STANDARD_DEVIATION 7.65 • n=42 Participants
Sex: Female, Male Female	2 Participants n=5 Participants	3 Participants n=7 Participants	5 Participants n=5 Participants	3 Participants n=4 Participants	2 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	3 Participants n=24 Participants	0 Participants n=42 Participants	18 Participants n=42 Participants
Sex: Female, Male Male	1 Participants n=5 Participants	4 Participants n=7 Participants	0 Participants n=5 Participants	4 Participants n=4 Participants	1 Participants n=21 Participants	4 Participants n=8 Participants	2 Participants n=8 Participants	2 Participants n=24 Participants	5 Participants n=42 Participants	23 Participants n=42 Participants
Race/Ethnicity, Customized African	0 participants n=5 Participants	0 participants n=7 Participants	1 participants n=5 Participants	0 participants n=4 Participants	1 participants n=21 Participants	0 participants n=8 Participants	0 participants n=8 Participants	0 participants n=24 Participants	0 participants n=42 Participants	2 participants n=42 Participants
Race/Ethnicity, Customized Caucasian	3 participants n=5 Participants	6 participants n=7 Participants	4 participants n=5 Participants	7 participants n=4 Participants	2 participants n=21 Participants	4 participants n=8 Participants	2 participants n=8 Participants	5 participants n=24 Participants	5 participants n=42 Participants	38 participants n=42 Participants
Race/Ethnicity, Customized Hispanic	0 participants n=5 Participants	1 participants n=7 Participants	0 participants n=5 Participants	0 participants n=4 Participants	0 participants n=21 Participants	0 participants n=8 Participants	0 participants n=8 Participants	0 participants n=24 Participants	0 participants n=42 Participants	1 participants n=42 Participants
Region of Enrollment United States	3 participants n=5 Participants	7 participants n=7 Participants	5 participants n=5 Participants	7 participants n=4 Participants	3 participants n=21 Participants	4 participants n=8 Participants	2 participants n=8 Participants	5 participants n=24 Participants	5 participants n=42 Participants	41 participants n=42 Participants
Body Surface Area	1.76 meters squared (m^2) STANDARD_DEVIATION 0.11 • n=5 Participants	2.10 meters squared (m^2) STANDARD_DEVIATION 0.13 • n=7 Participants	1.66 meters squared (m^2) STANDARD_DEVIATION 0.14 • n=5 Participants	1.94 meters squared (m^2) STANDARD_DEVIATION 0.29 • n=4 Participants	1.77 meters squared (m^2) STANDARD_DEVIATION 0.46 • n=21 Participants	2.11 meters squared (m^2) STANDARD_DEVIATION 0.33 • n=8 Participants	2.07 meters squared (m^2) STANDARD_DEVIATION 0.14 • n=8 Participants	1.90 meters squared (m^2) STANDARD_DEVIATION 0.30 • n=24 Participants	2.04 meters squared (m^2) STANDARD_DEVIATION 0.15 • n=42 Participants	1.94 meters squared (m^2) STANDARD_DEVIATION 0.27 • n=42 Participants
Eastern Cooperative Oncology Group (ECOG) performance 0	3 participants n=5 Participants	5 participants n=7 Participants	5 participants n=5 Participants	7 participants n=4 Participants	2 participants n=21 Participants	4 participants n=8 Participants	2 participants n=8 Participants	3 participants n=24 Participants	5 participants n=42 Participants	36 participants n=42 Participants
Eastern Cooperative Oncology Group (ECOG) performance 1	0 participants n=5 Participants	2 participants n=7 Participants	0 participants n=5 Participants	0 participants n=4 Participants	1 participants n=21 Participants	0 participants n=8 Participants	0 participants n=8 Participants	2 participants n=24 Participants	0 participants n=42 Participants	5 participants n=42 Participants
Basis of Diagnosis Cytological	1 participants n=5 Participants	1 participants n=7 Participants	1 participants n=5 Participants	1 participants n=4 Participants	2 participants n=21 Participants	0 participants n=8 Participants	1 participants n=8 Participants	1 participants n=24 Participants	0 participants n=42 Participants	8 participants n=42 Participants
Basis of Diagnosis Histopathological	2 participants n=5 Participants	6 participants n=7 Participants	4 participants n=5 Participants	6 participants n=4 Participants	1 participants n=21 Participants	4 participants n=8 Participants	1 participants n=8 Participants	4 participants n=24 Participants	5 participants n=42 Participants	33 participants n=42 Participants
Initial Pathological Tumor Diagnosis Mesothelioma	2 participants n=5 Participants	3 participants n=7 Participants	1 participants n=5 Participants	0 participants n=4 Participants	0 participants n=21 Participants	1 participants n=8 Participants	0 participants n=8 Participants	1 participants n=24 Participants	1 participants n=42 Participants	9 participants n=42 Participants
Initial Pathological Tumor Diagnosis Non-small cell lung carcinoma (NSCLC)	0 participants n=5 Participants	0 participants n=7 Participants	3 participants n=5 Participants	1 participants n=4 Participants	1 participants n=21 Participants	0 participants n=8 Participants	0 participants n=8 Participants	1 participants n=24 Participants	1 participants n=42 Participants	7 participants n=42 Participants
Initial Pathological Tumor Diagnosis Leimyosarcoma	0 participants n=5 Participants	2 participants n=7 Participants	0 participants n=5 Participants	0 participants n=4 Participants	0 participants n=21 Participants	1 participants n=8 Participants	0 participants n=8 Participants	0 participants n=24 Participants	0 participants n=42 Participants	3 participants n=42 Participants
Initial Pathological Tumor Diagnosis Esophagus	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	1 participants n=4 Participants	1 participants n=21 Participants	0 participants n=8 Participants	0 participants n=8 Participants	1 participants n=24 Participants	0 participants n=42 Participants	3 participants n=42 Participants
Initial Pathological Tumor Diagnosis Lung adenocarcinoma	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	0 participants n=4 Participants	0 participants n=21 Participants	0 participants n=8 Participants	1 participants n=8 Participants	1 participants n=24 Participants	1 participants n=42 Participants	3 participants n=42 Participants
Initial Pathological Tumor Diagnosis Rectum	0 participants n=5 Participants	1 participants n=7 Participants	0 participants n=5 Participants	0 participants n=4 Participants	0 participants n=21 Participants	1 participants n=8 Participants	0 participants n=8 Participants	0 participants n=24 Participants	0 participants n=42 Participants	2 participants n=42 Participants
Initial Pathological Tumor Diagnosis Small cell lung carcinoma (SCLC)	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	1 participants n=4 Participants	0 participants n=21 Participants	0 participants n=8 Participants	0 participants n=8 Participants	0 participants n=24 Participants	1 participants n=42 Participants	2 participants n=42 Participants
Initial Pathological Tumor Diagnosis Gastric	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	0 participants n=4 Participants	1 participants n=21 Participants	0 participants n=8 Participants	0 participants n=8 Participants	0 participants n=24 Participants	1 participants n=42 Participants	2 participants n=42 Participants
Initial Pathological Tumor Diagnosis Head and neck	1 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	0 participants n=4 Participants	0 participants n=21 Participants	0 participants n=8 Participants	0 participants n=8 Participants	0 participants n=24 Participants	0 participants n=42 Participants	1 participants n=42 Participants
Initial Pathological Tumor Diagnosis Adenocarcinoma not otherwise specified (NOS)	0 participants n=5 Participants	1 participants n=7 Participants	0 participants n=5 Participants	0 participants n=4 Participants	0 participants n=21 Participants	0 participants n=8 Participants	0 participants n=8 Participants	0 participants n=24 Participants	0 participants n=42 Participants	1 participants n=42 Participants
Initial Pathological Tumor Diagnosis Colon	0 participants n=5 Participants	0 participants n=7 Participants	1 participants n=5 Participants	0 participants n=4 Participants	0 participants n=21 Participants	0 participants n=8 Participants	0 participants n=8 Participants	0 participants n=24 Participants	0 participants n=42 Participants	1 participants n=42 Participants
Initial Pathological Tumor Diagnosis Breast	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	1 participants n=4 Participants	0 participants n=21 Participants	0 participants n=8 Participants	0 participants n=8 Participants	0 participants n=24 Participants	0 participants n=42 Participants	1 participants n=42 Participants
Initial Pathological Tumor Diagnosis Pancreas	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	1 participants n=4 Participants	0 participants n=21 Participants	0 participants n=8 Participants	0 participants n=8 Participants	0 participants n=24 Participants	0 participants n=42 Participants	1 participants n=42 Participants
Initial Pathological Tumor Diagnosis Cancer NOS	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	1 participants n=4 Participants	0 participants n=21 Participants	0 participants n=8 Participants	0 participants n=8 Participants	0 participants n=24 Participants	0 participants n=42 Participants	1 participants n=42 Participants
Initial Pathological Tumor Diagnosis Gall bladder	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	1 participants n=4 Participants	0 participants n=21 Participants	0 participants n=8 Participants	0 participants n=8 Participants	0 participants n=24 Participants	0 participants n=42 Participants	1 participants n=42 Participants
Initial Pathological Tumor Diagnosis Thymoma	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	0 participants n=4 Participants	0 participants n=21 Participants	1 participants n=8 Participants	0 participants n=8 Participants	0 participants n=24 Participants	0 participants n=42 Participants	1 participants n=42 Participants
Initial Pathological Tumor Diagnosis Adenoid	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	0 participants n=4 Participants	0 participants n=21 Participants	0 participants n=8 Participants	1 participants n=8 Participants	0 participants n=24 Participants	0 participants n=42 Participants	1 participants n=42 Participants
Initial Pathological Tumor Diagnosis Bile duct	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	0 participants n=4 Participants	0 participants n=21 Participants	0 participants n=8 Participants	0 participants n=8 Participants	1 participants n=24 Participants	0 participants n=42 Participants	1 participants n=42 Participants

PRIMARY outcome

Timeframe: Baseline up to Day 28 (Cycle 1)

Population: Safety population: all participants who have received at least 1 dose of the study drug.

Outcome measures

Outcome measures
Measure	LY2090314/Pemetrexed/Carboplatin n=41 Participants Cycle 1 (28 days) Cohorts 1 to 3 * Cycle 1 Day 1: 10-20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 or 6 mg/mL \* min Carb by intravenous infusion. Cohorts 4 to 9, Cohorts 7 to 9 were pretreated with 50 mg ranitidine intravenous-Cycle 1 Day 1: 40-120 mg LY2090314 by intravenous infusion. -Cycle 1 Day 8: 500 mg/m\^2 by Pem intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40-120 mg LY2090314 by intravenous infusion.	LY 20/Carb 6/Pem 500 (Cohort 3) * Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.	LY 40/Carb 6/Pem 500 (Cohorts 4 and 9) * Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion-followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 49 mg LY2090314 by intravenous infusion. Cohort 9, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 (Cohorts 5 and 7) * Cycle 1 Day 1 of 28-day cycle: 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. Cohort 7, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 120/Carb 6/Pem 500 (Cohort 6) * Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 by Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by pretreatment with 50 mg ranitidine intravenous and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 + R50 (Cohort 7) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 IV infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 40/Carb 6/Pem 500 + R50 (Cohort 9) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 intravenous Pem infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min by Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.
Recommended LY2090314 Dose for Phase 2 Studies (Maximum Tolerated Dose [MTD])	40 milligrams (mg)	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Cycle 1 Day 1 of a 28 day cycle

Population: All participants who received at least 1 dose of LY2090314 and had evaluable AUC0-∞ data, excluding 2 participants (1 in dose groups LY80 and 1 in dose group LY120) who received the wrong dose of LY2090314.

AUC0-∞ was calculated from the area under the concentration versus time curve from time 0 to infinity of LY2090314 when administered alone.

Outcome measures

Outcome measures
Measure	LY2090314/Pemetrexed/Carboplatin n=10 Participants Cycle 1 (28 days) Cohorts 1 to 3 * Cycle 1 Day 1: 10-20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 or 6 mg/mL \* min Carb by intravenous infusion. Cohorts 4 to 9, Cohorts 7 to 9 were pretreated with 50 mg ranitidine intravenous-Cycle 1 Day 1: 40-120 mg LY2090314 by intravenous infusion. -Cycle 1 Day 8: 500 mg/m\^2 by Pem intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40-120 mg LY2090314 by intravenous infusion.	LY 20/Carb 6/Pem 500 (Cohort 3) n=5 Participants * Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.	LY 40/Carb 6/Pem 500 (Cohorts 4 and 9) n=11 Participants * Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion-followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 49 mg LY2090314 by intravenous infusion. Cohort 9, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 (Cohorts 5 and 7) n=5 Participants * Cycle 1 Day 1 of 28-day cycle: 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. Cohort 7, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 120/Carb 6/Pem 500 (Cohort 6) n=3 Participants * Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 by Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) n=5 Participants * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by pretreatment with 50 mg ranitidine intravenous and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 + R50 (Cohort 7) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 IV infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 40/Carb 6/Pem 500 + R50 (Cohort 9) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 intravenous Pem infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min by Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.
Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of LY2090314	216 nanograms*hour per milliliter Geometric Coefficient of Variation 26.3	427 nanograms*hour per milliliter Geometric Coefficient of Variation 21.8	976 nanograms*hour per milliliter Geometric Coefficient of Variation 42.6	1870 nanograms*hour per milliliter Geometric Coefficient of Variation 76.7	3310 nanograms*hour per milliliter Geometric Coefficient of Variation 18.7	1600 nanograms*hour per milliliter Geometric Coefficient of Variation 47.3	—	—	—

SECONDARY outcome

Timeframe: Cycle 1 Day 8 of a 28-day cycle or Cycle 2 Day 1 of a 21-day cycle

Population: All participants who received at least 1 dose LY2090314 coadministered with Pem and Carb and had enough samples to allow estimation of AUC0-∞ parameters excluding 2 participants (1 in dose groups LY80 and 1 in dose group LY120) who received the incorrect dose of LY2090314.

AUC0-∞ was calculated from the area under the concentration versus time curves of LY2090314 from time zero to infinity when coadministered with Pem and Carb.

Outcome measures

Outcome measures
Measure	LY2090314/Pemetrexed/Carboplatin n=10 Participants Cycle 1 (28 days) Cohorts 1 to 3 * Cycle 1 Day 1: 10-20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 or 6 mg/mL \* min Carb by intravenous infusion. Cohorts 4 to 9, Cohorts 7 to 9 were pretreated with 50 mg ranitidine intravenous-Cycle 1 Day 1: 40-120 mg LY2090314 by intravenous infusion. -Cycle 1 Day 8: 500 mg/m\^2 by Pem intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40-120 mg LY2090314 by intravenous infusion.	LY 20/Carb 6/Pem 500 (Cohort 3) n=4 Participants * Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.	LY 40/Carb 6/Pem 500 (Cohorts 4 and 9) n=9 Participants * Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion-followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 49 mg LY2090314 by intravenous infusion. Cohort 9, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 (Cohorts 5 and 7) n=3 Participants * Cycle 1 Day 1 of 28-day cycle: 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. Cohort 7, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 120/Carb 6/Pem 500 (Cohort 6) n=1 Participants * Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 by Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) n=5 Participants * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by pretreatment with 50 mg ranitidine intravenous and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 + R50 (Cohort 7) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 IV infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 40/Carb 6/Pem 500 + R50 (Cohort 9) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 intravenous Pem infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min by Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.
PK Parameter: AUC0-∞ of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb)	192 nanograms*hour per milliliter Geometric Coefficient of Variation 48.2	404 nanograms*hour per milliliter Geometric Coefficient of Variation 33.2	938 nanograms*hour per milliliter Geometric Coefficient of Variation 33.5	1830 nanograms*hour per milliliter Geometric Coefficient of Variation 7.84	2190 nanograms*hour per milliliter Geometric Coefficient of Variation NA 1 participant analyzed, therefore, unable to calculate geometric coefficient of variation.	1570 nanograms*hour per milliliter Geometric Coefficient of Variation 36.5	—	—	—

SECONDARY outcome

Timeframe: Cycle 1 Day 1 of a 28-day cycle

Outcome measures

Outcome measures
Measure	LY2090314/Pemetrexed/Carboplatin n=10 Participants Cycle 1 (28 days) Cohorts 1 to 3 * Cycle 1 Day 1: 10-20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 or 6 mg/mL \* min Carb by intravenous infusion. Cohorts 4 to 9, Cohorts 7 to 9 were pretreated with 50 mg ranitidine intravenous-Cycle 1 Day 1: 40-120 mg LY2090314 by intravenous infusion. -Cycle 1 Day 8: 500 mg/m\^2 by Pem intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40-120 mg LY2090314 by intravenous infusion.	LY 20/Carb 6/Pem 500 (Cohort 3) n=5 Participants * Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.	LY 40/Carb 6/Pem 500 (Cohorts 4 and 9) n=11 Participants * Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion-followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 49 mg LY2090314 by intravenous infusion. Cohort 9, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 (Cohorts 5 and 7) n=5 Participants * Cycle 1 Day 1 of 28-day cycle: 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. Cohort 7, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 120/Carb 6/Pem 500 (Cohort 6) n=3 Participants * Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 by Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) n=5 Participants * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by pretreatment with 50 mg ranitidine intravenous and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 + R50 (Cohort 7) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 IV infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 40/Carb 6/Pem 500 + R50 (Cohort 9) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 intravenous Pem infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min by Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.
PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314	122 nanograms per milliliter Geometric Coefficient of Variation 21.5	246 nanograms per milliliter Geometric Coefficient of Variation 29.0	603 nanograms per milliliter Geometric Coefficient of Variation 47.7	898 nanograms per milliliter Geometric Coefficient of Variation 50.5	1700 nanograms per milliliter Geometric Coefficient of Variation 63.2	881 nanograms per milliliter Geometric Coefficient of Variation 53.3	—	—	—

SECONDARY outcome

Timeframe: Cycle 1 Day 8 of a 28-day cycle or Cycle 2 Day 1 of a 21-day cycle

Outcome measures

Outcome measures
Measure	LY2090314/Pemetrexed/Carboplatin n=10 Participants Cycle 1 (28 days) Cohorts 1 to 3 * Cycle 1 Day 1: 10-20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 or 6 mg/mL \* min Carb by intravenous infusion. Cohorts 4 to 9, Cohorts 7 to 9 were pretreated with 50 mg ranitidine intravenous-Cycle 1 Day 1: 40-120 mg LY2090314 by intravenous infusion. -Cycle 1 Day 8: 500 mg/m\^2 by Pem intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40-120 mg LY2090314 by intravenous infusion.	LY 20/Carb 6/Pem 500 (Cohort 3) n=4 Participants * Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.	LY 40/Carb 6/Pem 500 (Cohorts 4 and 9) n=9 Participants * Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion-followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 49 mg LY2090314 by intravenous infusion. Cohort 9, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 (Cohorts 5 and 7) n=3 Participants * Cycle 1 Day 1 of 28-day cycle: 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. Cohort 7, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 120/Carb 6/Pem 500 (Cohort 6) n=1 Participants * Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 by Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) n=5 Participants * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by pretreatment with 50 mg ranitidine intravenous and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 + R50 (Cohort 7) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 IV infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 40/Carb 6/Pem 500 + R50 (Cohort 9) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 intravenous Pem infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min by Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.
PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb)	106 nanograms per milliliter Geometric Coefficient of Variation 57.5	271 nanograms per milliliter Geometric Coefficient of Variation 62.5	657 nanograms per milliliter Geometric Coefficient of Variation 44.1	1150 nanograms per milliliter Geometric Coefficient of Variation 27.8	768 nanograms per milliliter Geometric Coefficient of Variation NA 1 participant analyzed, therefore, unable to calculate geometric coefficient of variation.	1040 nanograms per milliliter Geometric Coefficient of Variation 48.2	—	—	—

SECONDARY outcome

Timeframe: Baseline up to Cycle 9 (Cycle 1 was 28 days, Cycles 2 to 9 were 21 days)

Population: Analysis population: all participants who received at least 1 dose of study drug and had tumor response assessment.

Best overall observed tumor response at any point during the study until disease progression/recurrence defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR) was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) and normalization of tumor marker level of non-target lesions; Partial Response (PR) was defined as at least 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) was defined as at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase over nadir; Stable Disease (SD) was defined as small changes that did not meet above criteria.

Outcome measures

Outcome measures
Measure	LY2090314/Pemetrexed/Carboplatin n=3 Participants Cycle 1 (28 days) Cohorts 1 to 3 * Cycle 1 Day 1: 10-20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 or 6 mg/mL \* min Carb by intravenous infusion. Cohorts 4 to 9, Cohorts 7 to 9 were pretreated with 50 mg ranitidine intravenous-Cycle 1 Day 1: 40-120 mg LY2090314 by intravenous infusion. -Cycle 1 Day 8: 500 mg/m\^2 by Pem intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40-120 mg LY2090314 by intravenous infusion.	LY 20/Carb 6/Pem 500 (Cohort 3) n=7 Participants * Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.	LY 40/Carb 6/Pem 500 (Cohorts 4 and 9) n=5 Participants * Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion-followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 49 mg LY2090314 by intravenous infusion. Cohort 9, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 (Cohorts 5 and 7) n=7 Participants * Cycle 1 Day 1 of 28-day cycle: 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. Cohort 7, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 120/Carb 6/Pem 500 (Cohort 6) n=3 Participants * Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 by Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) n=4 Participants * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by pretreatment with 50 mg ranitidine intravenous and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 + R50 (Cohort 7) n=2 Participants * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 IV infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) n=5 Participants * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 40/Carb 6/Pem 500 + R50 (Cohort 9) n=5 Participants * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 intravenous Pem infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min by Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.
Number of Participants With Best Overall Tumor Response Unknown (discontinued before response assessment)	1 participants	1 participants	1 participants	0 participants	2 participants	0 participants	0 participants	0 participants	1 participants
Number of Participants With Best Overall Tumor Response CR	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants
Number of Participants With Best Overall Tumor Response PR	0 participants	0 participants	1 participants	1 participants	0 participants	0 participants	1 participants	1 participants	0 participants
Number of Participants With Best Overall Tumor Response SD	2 participants	4 participants	2 participants	2 participants	0 participants	0 participants	1 participants	1 participants	2 participants
Number of Participants With Best Overall Tumor Response PD	0 participants	2 participants	1 participants	3 participants	1 participants	0 participants	0 participants	2 participants	2 participants

SECONDARY outcome

Timeframe: Cycle 1 Day 8 of 28-day cycle and Cycle 2 up to Cycle 10 Day 1 of 21-day cycle

Population: All participants who were treated with Pem and Carb (doublet therapy) or who were treated with Pem, Carb and LY2090314 (triplet therapy) and had evaluable AUC0-∞ Pem data.

AUC0-∞ was calculated from the area under the concentration versus time curves of Pem given as a single dose with Carb (doublet therapy) and when co-administered with Carb and LY2090314 (triplet therapy).

Outcome measures

Outcome measures
Measure	LY2090314/Pemetrexed/Carboplatin n=33 Participants Cycle 1 (28 days) Cohorts 1 to 3 * Cycle 1 Day 1: 10-20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 or 6 mg/mL \* min Carb by intravenous infusion. Cohorts 4 to 9, Cohorts 7 to 9 were pretreated with 50 mg ranitidine intravenous-Cycle 1 Day 1: 40-120 mg LY2090314 by intravenous infusion. -Cycle 1 Day 8: 500 mg/m\^2 by Pem intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40-120 mg LY2090314 by intravenous infusion.	LY 20/Carb 6/Pem 500 (Cohort 3) n=36 Participants * Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.	LY 40/Carb 6/Pem 500 (Cohorts 4 and 9) * Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion-followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 49 mg LY2090314 by intravenous infusion. Cohort 9, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 (Cohorts 5 and 7) * Cycle 1 Day 1 of 28-day cycle: 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. Cohort 7, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 120/Carb 6/Pem 500 (Cohort 6) * Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 by Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by pretreatment with 50 mg ranitidine intravenous and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 + R50 (Cohort 7) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 IV infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 40/Carb 6/Pem 500 + R50 (Cohort 9) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 intravenous Pem infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min by Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.
Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of Pemetrexed (Pem)	212 hours*nanograms/milliliter/ milligram Geometric Coefficient of Variation 34.4	202 hours*nanograms/milliliter/ milligram Geometric Coefficient of Variation 37.5	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Cycle 1 Day 8 of 28-day cycle and Cycle 2 up to Cycle 10 Day 1 of 21-day cycle

Population: All participants who were treated with Pem and Carb (doublet therapy) or who were treated with Pem, Carb and LY2090314 (triplet therapy) and had evaluable Cmax Pem data.

Cmax of Pem given as a single dose with Carb (doublet therapy) and when coadministered with Carb and LY2090314 (triplet therapy).

Outcome measures

Outcome measures
Measure	LY2090314/Pemetrexed/Carboplatin n=33 Participants Cycle 1 (28 days) Cohorts 1 to 3 * Cycle 1 Day 1: 10-20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 or 6 mg/mL \* min Carb by intravenous infusion. Cohorts 4 to 9, Cohorts 7 to 9 were pretreated with 50 mg ranitidine intravenous-Cycle 1 Day 1: 40-120 mg LY2090314 by intravenous infusion. -Cycle 1 Day 8: 500 mg/m\^2 by Pem intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40-120 mg LY2090314 by intravenous infusion.	LY 20/Carb 6/Pem 500 (Cohort 3) n=36 Participants * Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.	LY 40/Carb 6/Pem 500 (Cohorts 4 and 9) * Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion-followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 49 mg LY2090314 by intravenous infusion. Cohort 9, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 (Cohorts 5 and 7) * Cycle 1 Day 1 of 28-day cycle: 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. Cohort 7, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 120/Carb 6/Pem 500 (Cohort 6) * Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 by Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by pretreatment with 50 mg ranitidine intravenous and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 + R50 (Cohort 7) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 IV infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 40/Carb 6/Pem 500 + R50 (Cohort 9) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 intravenous Pem infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min by Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.
PK Parameter: Maximum Plasma Concentration (Cmax) of Pemetrexed (Pem)	109 nanogram per milliliter per milligram Geometric Coefficient of Variation 38.0	108 nanogram per milliliter per milligram Geometric Coefficient of Variation 43.1	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Cycle 1 Day 8 of 28-day cycle and Cycle 2 up to Cycle 9: Day 1 of 21-day cycle

Population: All participants who were treated with Pem and Carb (doublet therapy) or Pem, Carb and LY2090314 (triplet therapy) and who had evaluable Carb AUC0-∞ data.

AUC0-∞ of free Carb was calculated from the area under the concentration versus time curves of Carb given as a single dose with Pem (doublet therapy) and when co-administered with Pem and LY2090314 (triplet therapy).

Outcome measures

Outcome measures
Measure	LY2090314/Pemetrexed/Carboplatin n=32 Participants Cycle 1 (28 days) Cohorts 1 to 3 * Cycle 1 Day 1: 10-20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 or 6 mg/mL \* min Carb by intravenous infusion. Cohorts 4 to 9, Cohorts 7 to 9 were pretreated with 50 mg ranitidine intravenous-Cycle 1 Day 1: 40-120 mg LY2090314 by intravenous infusion. -Cycle 1 Day 8: 500 mg/m\^2 by Pem intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40-120 mg LY2090314 by intravenous infusion.	LY 20/Carb 6/Pem 500 (Cohort 3) n=35 Participants * Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.	LY 40/Carb 6/Pem 500 (Cohorts 4 and 9) * Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion-followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 49 mg LY2090314 by intravenous infusion. Cohort 9, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 (Cohorts 5 and 7) * Cycle 1 Day 1 of 28-day cycle: 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. Cohort 7, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 120/Carb 6/Pem 500 (Cohort 6) * Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 by Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by pretreatment with 50 mg ranitidine intravenous and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 + R50 (Cohort 7) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 IV infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 40/Carb 6/Pem 500 + R50 (Cohort 9) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 intravenous Pem infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min by Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.
PK Parameter: AUC0-∞ of Free Carboplatin (Carb)	81.6 hours*nanograms per milliliter per mg Geometric Coefficient of Variation 41.8	88.1 hours*nanograms per milliliter per mg Geometric Coefficient of Variation 49.2	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Cycle 1, Day 8 of 28-day cycle and Cycle 2 up to Cycle 9: Day 1 of 21-day cycle

Population: All participants who were treated with Pem and Carb (doublet therapy) or who were treated with Pem, Carb and LY2090314 (triplet therapy) and had evaluable Carb Cmax data.

Cmax of free Carb given as a single dose with Pem (doublet therapy) and when co-administered with Pem and LY2090314 (triplet therapy).

Outcome measures

Outcome measures
Measure	LY2090314/Pemetrexed/Carboplatin n=32 Participants Cycle 1 (28 days) Cohorts 1 to 3 * Cycle 1 Day 1: 10-20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 5 or 6 mg/mL \* min Carb by intravenous infusion. Cohorts 4 to 9, Cohorts 7 to 9 were pretreated with 50 mg ranitidine intravenous-Cycle 1 Day 1: 40-120 mg LY2090314 by intravenous infusion. -Cycle 1 Day 8: 500 mg/m\^2 by Pem intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40-120 mg LY2090314 by intravenous infusion.	LY 20/Carb 6/Pem 500 (Cohort 3) n=35 Participants * Cycle 1 Day 1 of 28-day cycle: 20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.	LY 40/Carb 6/Pem 500 (Cohorts 4 and 9) * Cycle 1 Day 1 of 28-day cycle: 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion-followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 49 mg LY2090314 by intravenous infusion. Cohort 9, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 (Cohorts 5 and 7) * Cycle 1 Day 1 of 28-day cycle: 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. Cohort 7, LY2090314 pretreated with 50 mg ranitidine intravenous. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 120/Carb 6/Pem 500 (Cohort 6) * Cycle 1 Day 1 of 28-day cycle: 120 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 by Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by pretreatment with 50 mg ranitidine intravenous and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 80/Carb 6/Pem 500 + R50 (Cohort 7) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 10: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 IV infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 40/Carb 6/Pem 500 + R50 (Cohort 9) * Cycle 1 Day 1 of 28-day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28-day cycle 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21-day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 intravenous Pem infusion. * Cycle 3 up to Cycle 9: Day 1 of 21-day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min by Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion. Based on I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.
PK Parameter: Cmax of Free Carboplatin	24.0 nanograms/milliliter/milligram Geometric Coefficient of Variation 43.9	25.5 nanograms/milliliter/milligram Geometric Coefficient of Variation 46.0	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline, Cycle 1 , Day 1 of a 28-day cycle and Cycle 2 up to Cycle 9: Day 1 of 21-day cycles

Population: There was insufficient data from participants who received at least 1 dose of LY2090314 to perform β-catenin modeling, thus zero participants were analyzed.

PD change from baseline to endpoint (up to Cycle 9) in β-catenin levels in peripheral blood mononuclear cells (PBMCs) following the administration of LY2090314 given alone and in combination with Pem and Carb. This outcome measure was not analyzed due to insufficient data.

Outcome measures

Outcome data not reported

Adverse Events

LY 10/Carb 5/Pem 500 (Cohort 1)

Serious events: 1 serious events

Other events: 3 other events

Deaths: 0 deaths

LY 10/Carb 6/Pem 500 (Cohort 2)

Serious events: 3 serious events

Other events: 7 other events

Deaths: 0 deaths

LY 20/Carb 6/Pem 500 (Cohort 3)

Serious events: 3 serious events

Other events: 5 other events

Deaths: 0 deaths

LY 40/Carb 6/Pem 500 (Cohort 4)

Serious events: 2 serious events

Other events: 7 other events

Deaths: 0 deaths

LY 80/Carb 6/Pem 500 (Cohort 5)

Serious events: 1 serious events

Other events: 3 other events

Deaths: 0 deaths

LY 120/Carb 6/Pem 500 (Cohort 6)

Serious events: 1 serious events

Other events: 3 other events

Deaths: 0 deaths

LY 80/Carb 6/Pem 500 + R50 (Cohort 7)

Serious events: 1 serious events

Other events: 2 other events

Deaths: 0 deaths

LY 60/Carb 6/Pem 500 + R50 (Cohort 8)

Serious events: 0 serious events

Other events: 5 other events

Deaths: 0 deaths

LY 40/Carb 6/Pem 500 + R50 (Cohort 9)

Serious events: 1 serious events

Other events: 5 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	LY 10/Carb 5/Pem 500 (Cohort 1) n=3 participants at risk * Cycle 1 Day 1 of 28 day cycle: 10 mg LY2090314 administered by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem administered by intravenous infusion followed by AUC 5 mg/mL \* min Carb administered by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem administered by intravenous infusion followed by AUC 5 mg/mL \* min Carb administered by intravenous infusion followed by 10 mg LY2090314 administered by intravenous infusion.	LY 10/Carb 6/Pem 500 (Cohort 2) n=7 participants at risk * Cycle 1 Day 1 of 28 day cycle: 10 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 by Pem intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 10 mg LY2090314 by intravenous infusion.	LY 20/Carb 6/Pem 500 (Cohort 3) n=5 participants at risk * Cycle 1 Day 1 of 28 day cycle: 20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.	LY 40/Carb 6/Pem 500 (Cohort 4) n=7 participants at risk * Cycle 1 Day 1 of 28 day cycle: 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.	LY 80/Carb 6/Pem 500 (Cohort 5) n=3 participants at risk * Cycle 1 Day 1 of 28 day cycle: 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion.	LY 120/Carb 6/Pem 500 (Cohort 6) n=4 participants at risk * Cycle 1 Day 1 of 28 day cycle: 120 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.	LY 80/Carb 6/Pem 500 + R50 (Cohort 7) n=2 participants at risk * Cycle 1 Day 1 of 28 day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 intravenous infusion. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) n=5 participants at risk * Cycle 1 Day 1 of 28 day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 40/Carb 6/Pem 500 + R50 (Cohort 9) n=5 participants at risk * Cycle 1 Day 1 of 28 day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40mmg LY2090314 40 mg by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.
Cardiac disorders Angina pectoris	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	25.0% 1/4 • Number of events 1	0.00% 0/2	0.00% 0/5	0.00% 0/5
Gastrointestinal disorders Nausea	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Gastrointestinal disorders Vomiting	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
General disorders Chest pain	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	0.00% 0/5	0.00% 0/5
General disorders Pyrexia	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Infections and infestations Pneumonia	33.3% 1/3 • Number of events 1	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Infections and infestations Pseudomembranous colitis	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Metabolism and nutrition disorders Dehydration	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Psychiatric disorders Panic attack	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Vascular disorders Deep vein thrombosis	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5

Other adverse events

Other adverse events
Measure	LY 10/Carb 5/Pem 500 (Cohort 1) n=3 participants at risk * Cycle 1 Day 1 of 28 day cycle: 10 mg LY2090314 administered by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem administered by intravenous infusion followed by AUC 5 mg/mL \* min Carb administered by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem administered by intravenous infusion followed by AUC 5 mg/mL \* min Carb administered by intravenous infusion followed by 10 mg LY2090314 administered by intravenous infusion.	LY 10/Carb 6/Pem 500 (Cohort 2) n=7 participants at risk * Cycle 1 Day 1 of 28 day cycle: 10 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 by Pem intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 10 mg LY2090314 by intravenous infusion.	LY 20/Carb 6/Pem 500 (Cohort 3) n=5 participants at risk * Cycle 1 Day 1 of 28 day cycle: 20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion.	LY 40/Carb 6/Pem 500 (Cohort 4) n=7 participants at risk * Cycle 1 Day 1 of 28 day cycle: 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion.	LY 80/Carb 6/Pem 500 (Cohort 5) n=3 participants at risk * Cycle 1 Day 1 of 28 day cycle: 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion.	LY 120/Carb 6/Pem 500 (Cohort 6) n=4 participants at risk * Cycle 1 Day 1 of 28 day cycle: 120 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion.	LY 80/Carb 6/Pem 500 + R50 (Cohort 7) n=2 participants at risk * Cycle 1 Day 1 of 28 day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 intravenous infusion. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 60/Carb 6/Pem 500 + R50 (Cohort 8) n=5 participants at risk * Cycle 1 Day 1 of 28 day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.	LY 40/Carb 6/Pem 500 + R50 (Cohort 9) n=5 participants at risk * Cycle 1 Day 1 of 28 day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40mmg LY2090314 40 mg by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain.
Eye disorders Asthenopia	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Ear and labyrinth disorders Tinnitus	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Blood and lymphatic system disorders Anaemia	66.7% 2/3 • Number of events 3	85.7% 6/7 • Number of events 8	100.0% 5/5 • Number of events 5	71.4% 5/7 • Number of events 5	66.7% 2/3 • Number of events 3	0.00% 0/4	50.0% 1/2 • Number of events 1	80.0% 4/5 • Number of events 4	60.0% 3/5 • Number of events 5
Blood and lymphatic system disorders Leukocytosis	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	0.00% 0/5	0.00% 0/5
Blood and lymphatic system disorders Leukopenia	0.00% 0/3	57.1% 4/7 • Number of events 4	20.0% 1/5 • Number of events 1	42.9% 3/7 • Number of events 8	66.7% 2/3 • Number of events 3	0.00% 0/4	50.0% 1/2 • Number of events 2	40.0% 2/5 • Number of events 2	20.0% 1/5 • Number of events 2
Blood and lymphatic system disorders Lymphopenia	0.00% 0/3	57.1% 4/7 • Number of events 4	20.0% 1/5 • Number of events 1	42.9% 3/7 • Number of events 4	0.00% 0/3	25.0% 1/4 • Number of events 1	0.00% 0/2	0.00% 0/5	0.00% 0/5
Blood and lymphatic system disorders Neutropenia	0.00% 0/3	57.1% 4/7 • Number of events 7	40.0% 2/5 • Number of events 6	71.4% 5/7 • Number of events 14	100.0% 3/3 • Number of events 4	0.00% 0/4	50.0% 1/2 • Number of events 1	60.0% 3/5 • Number of events 6	40.0% 2/5 • Number of events 4
Blood and lymphatic system disorders Thrombocytopenia	66.7% 2/3 • Number of events 2	42.9% 3/7 • Number of events 8	40.0% 2/5 • Number of events 3	85.7% 6/7 • Number of events 17	66.7% 2/3 • Number of events 5	0.00% 0/4	100.0% 2/2 • Number of events 5	80.0% 4/5 • Number of events 8	60.0% 3/5 • Number of events 9
Cardiac disorders Bundle branch block left	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Cardiac disorders Cardiac flutter	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Cardiac disorders Palpitations	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	33.3% 1/3 • Number of events 1	0.00% 0/4	50.0% 1/2 • Number of events 1	0.00% 0/5	0.00% 0/5
Eye disorders Cataract	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Eye disorders Eye irritation	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	20.0% 1/5 • Number of events 1	0.00% 0/5
Eye disorders Lacrimation increased	33.3% 1/3 • Number of events 1	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	20.0% 1/5 • Number of events 1	0.00% 0/5
Eye disorders Vision blurred	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	0.00% 0/5	0.00% 0/5
Eye disorders Visual impairment	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	33.3% 1/3 • Number of events 1	25.0% 1/4 • Number of events 1	0.00% 0/2	0.00% 0/5	0.00% 0/5
Eye disorders Vitreous floaters	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	20.0% 1/5 • Number of events 1	0.00% 0/5
Gastrointestinal disorders Abdominal discomfort	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Gastrointestinal disorders Abdominal distension	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	0.00% 0/7	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Gastrointestinal disorders Abdominal pain	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	42.9% 3/7 • Number of events 3	66.7% 2/3 • Number of events 3	50.0% 2/4 • Number of events 2	50.0% 1/2 • Number of events 1	40.0% 2/5 • Number of events 2	0.00% 0/5
Gastrointestinal disorders Abdominal pain lower	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	20.0% 1/5 • Number of events 1	0.00% 0/5
Gastrointestinal disorders Abdominal pain upper	0.00% 0/3	28.6% 2/7 • Number of events 2	0.00% 0/5	28.6% 2/7 • Number of events 2	0.00% 0/3	25.0% 1/4 • Number of events 1	0.00% 0/2	20.0% 1/5 • Number of events 2	20.0% 1/5 • Number of events 1
Gastrointestinal disorders Ascites	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	20.0% 1/5 • Number of events 1	0.00% 0/5
Gastrointestinal disorders Constipation	66.7% 2/3 • Number of events 2	14.3% 1/7 • Number of events 1	40.0% 2/5 • Number of events 2	28.6% 2/7 • Number of events 2	66.7% 2/3 • Number of events 3	0.00% 0/4	100.0% 2/2 • Number of events 2	0.00% 0/5	40.0% 2/5 • Number of events 2
Gastrointestinal disorders Diarrhoea	0.00% 0/3	14.3% 1/7 • Number of events 1	20.0% 1/5 • Number of events 1	28.6% 2/7 • Number of events 2	66.7% 2/3 • Number of events 2	0.00% 0/4	0.00% 0/2	20.0% 1/5 • Number of events 1	20.0% 1/5 • Number of events 1
Gastrointestinal disorders Dyspepsia	0.00% 0/3	0.00% 0/7	40.0% 2/5 • Number of events 2	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	20.0% 1/5 • Number of events 1	0.00% 0/5
Gastrointestinal disorders Dysphagia	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	20.0% 1/5 • Number of events 1	0.00% 0/5
Gastrointestinal disorders Flatulence	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	20.0% 1/5 • Number of events 1	20.0% 1/5 • Number of events 1
Gastrointestinal disorders Haematochezia	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Gastrointestinal disorders Haemorrhoids	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Gastrointestinal disorders Nausea	33.3% 1/3 • Number of events 3	85.7% 6/7 • Number of events 8	60.0% 3/5 • Number of events 5	57.1% 4/7 • Number of events 5	33.3% 1/3 • Number of events 1	25.0% 1/4 • Number of events 1	100.0% 2/2 • Number of events 3	40.0% 2/5 • Number of events 3	60.0% 3/5 • Number of events 5
Gastrointestinal disorders Retching	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Gastrointestinal disorders Toothache	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Gastrointestinal disorders Vomiting	33.3% 1/3 • Number of events 1	28.6% 2/7 • Number of events 2	40.0% 2/5 • Number of events 3	42.9% 3/7 • Number of events 4	100.0% 3/3 • Number of events 3	25.0% 1/4 • Number of events 1	100.0% 2/2 • Number of events 3	20.0% 1/5 • Number of events 1	0.00% 0/5
General disorders Asthenia	0.00% 0/3	14.3% 1/7 • Number of events 1	20.0% 1/5 • Number of events 1	14.3% 1/7 • Number of events 1	33.3% 1/3 • Number of events 1	25.0% 1/4 • Number of events 1	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
General disorders Catheter site phlebitis	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
General disorders Chest discomfort	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	25.0% 1/4 • Number of events 1	50.0% 1/2 • Number of events 1	0.00% 0/5	20.0% 1/5 • Number of events 1
General disorders Chest pain	0.00% 0/3	28.6% 2/7 • Number of events 2	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	25.0% 1/4 • Number of events 1	50.0% 1/2 • Number of events 1	0.00% 0/5	0.00% 0/5
General disorders Chills	0.00% 0/3	14.3% 1/7 • Number of events 1	40.0% 2/5 • Number of events 2	14.3% 1/7 • Number of events 1	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	40.0% 2/5 • Number of events 2	20.0% 1/5 • Number of events 1
General disorders Fatigue	100.0% 3/3 • Number of events 3	85.7% 6/7 • Number of events 8	100.0% 5/5 • Number of events 6	71.4% 5/7 • Number of events 6	66.7% 2/3 • Number of events 2	0.00% 0/4	50.0% 1/2 • Number of events 1	80.0% 4/5 • Number of events 4	80.0% 4/5 • Number of events 4
General disorders Influenza like illness	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
General disorders Infusion site reaction	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
General disorders Mucosal inflammation	33.3% 1/3 • Number of events 1	0.00% 0/7	40.0% 2/5 • Number of events 2	28.6% 2/7 • Number of events 2	33.3% 1/3 • Number of events 2	0.00% 0/4	100.0% 2/2 • Number of events 2	0.00% 0/5	0.00% 0/5
General disorders Nodule	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	25.0% 1/4 • Number of events 1	0.00% 0/2	0.00% 0/5	0.00% 0/5
General disorders Oedema peripheral	33.3% 1/3 • Number of events 1	14.3% 1/7 • Number of events 1	20.0% 1/5 • Number of events 1	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	0.00% 0/5	0.00% 0/5
General disorders Pyrexia	0.00% 0/3	42.9% 3/7 • Number of events 4	60.0% 3/5 • Number of events 6	28.6% 2/7 • Number of events 2	33.3% 1/3 • Number of events 2	0.00% 0/4	0.00% 0/2	20.0% 1/5 • Number of events 1	40.0% 2/5 • Number of events 3
Immune system disorders Drug hypersensitivity	33.3% 1/3 • Number of events 1	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Immune system disorders Hypersensitivity	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	20.0% 1/5 • Number of events 1	0.00% 0/5
Infections and infestations Gastroenteritis	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Infections and infestations Lung infection	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Infections and infestations Nasopharyngitis	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Infections and infestations Streptococcal bacteraemia	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Infections and infestations Urinary tract infection	0.00% 0/3	0.00% 0/7	0.00% 0/5	28.6% 2/7 • Number of events 4	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Injury, poisoning and procedural complications Incision site pain	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	40.0% 2/5 • Number of events 5	0.00% 0/5
Injury, poisoning and procedural complications Scratch	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	20.0% 1/5 • Number of events 1	0.00% 0/5
Investigations Alanine aminotransferase increased	0.00% 0/3	14.3% 1/7 • Number of events 1	40.0% 2/5 • Number of events 3	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Investigations Antineutrophil cytoplasmic antibody increased	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	0.00% 0/5	0.00% 0/5
Investigations Aspartate aminotransferase increased	0.00% 0/3	14.3% 1/7 • Number of events 1	20.0% 1/5 • Number of events 1	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Investigations Blood alkaline phosphatase increased	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Investigations Blood creatinine increased	33.3% 1/3 • Number of events 1	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	20.0% 1/5 • Number of events 1	0.00% 0/5
Investigations Blood culture positive	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Investigations Blood glucose increased	33.3% 1/3 • Number of events 1	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Investigations Blood magnesium decreased	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 2	0.00% 0/5	0.00% 0/5
Investigations Blood urine present	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Investigations Electrocardiogram qt prolonged	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	25.0% 1/4 • Number of events 1	0.00% 0/2	20.0% 1/5 • Number of events 1	0.00% 0/5
Investigations Glomerular filtration rate decreased	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Investigations Haematocrit decreased	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Investigations Haemoglobin decreased	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Investigations Neutrophil count decreased	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	0.00% 0/5	0.00% 0/5
Investigations Weight decreased	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Investigations White blood cell count decreased	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	20.0% 1/5 • Number of events 1	60.0% 3/5 • Number of events 4
Investigations White blood cell count increased	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	0.00% 0/5	0.00% 0/5
Metabolism and nutrition disorders Decreased appetite	0.00% 0/3	42.9% 3/7 • Number of events 3	40.0% 2/5 • Number of events 2	57.1% 4/7 • Number of events 4	66.7% 2/3 • Number of events 3	25.0% 1/4 • Number of events 1	50.0% 1/2 • Number of events 1	60.0% 3/5 • Number of events 3	0.00% 0/5
Metabolism and nutrition disorders Dehydration	0.00% 0/3	0.00% 0/7	0.00% 0/5	28.6% 2/7 • Number of events 2	66.7% 2/3 • Number of events 4	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/3	57.1% 4/7 • Number of events 6	20.0% 1/5 • Number of events 1	42.9% 3/7 • Number of events 4	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	0.00% 0/5	20.0% 1/5 • Number of events 1
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Metabolism and nutrition disorders Hyperphosphatasaemia	0.00% 0/3	28.6% 2/7 • Number of events 2	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	14.3% 1/7 • Number of events 4	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	42.9% 3/7 • Number of events 3	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	0.00% 0/5	0.00% 0/5
Metabolism and nutrition disorders Type 2 diabetes mellitus	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Musculoskeletal and connective tissue disorders Arthralgia	33.3% 1/3 • Number of events 1	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 2	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Musculoskeletal and connective tissue disorders Back pain	66.7% 2/3 • Number of events 2	28.6% 2/7 • Number of events 3	0.00% 0/5	28.6% 2/7 • Number of events 2	0.00% 0/3	25.0% 1/4 • Number of events 1	0.00% 0/2	0.00% 0/5	40.0% 2/5 • Number of events 2
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/3	14.3% 1/7 • Number of events 2	0.00% 0/5	0.00% 0/7	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	0.00% 0/7	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	0.00% 0/5	20.0% 1/5 • Number of events 1
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Nervous system disorders Burning sensation	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Nervous system disorders Dizziness	33.3% 1/3 • Number of events 1	0.00% 0/7	0.00% 0/5	28.6% 2/7 • Number of events 2	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	20.0% 1/5 • Number of events 1	40.0% 2/5 • Number of events 2
Nervous system disorders Dysgeusia	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	20.0% 1/5 • Number of events 1	0.00% 0/5
Nervous system disorders Headache	0.00% 0/3	14.3% 1/7 • Number of events 1	40.0% 2/5 • Number of events 2	42.9% 3/7 • Number of events 3	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Nervous system disorders Hypogeusia	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Nervous system disorders Neuropathy peripheral	100.0% 3/3 • Number of events 3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Nervous system disorders Paraesthesia	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	0.00% 0/5	20.0% 1/5 • Number of events 1
Nervous system disorders Somnolence	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Nervous system disorders Syncope	33.3% 1/3 • Number of events 1	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Psychiatric disorders Agitation	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Psychiatric disorders Anxiety	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Psychiatric disorders Confusional state	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	28.6% 2/7 • Number of events 2	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Psychiatric disorders Insomnia	33.3% 1/3 • Number of events 1	0.00% 0/7	0.00% 0/5	0.00% 0/7	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	20.0% 1/5 • Number of events 1	0.00% 0/5
Renal and urinary disorders Dysuria	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Renal and urinary disorders Renal pain	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Renal and urinary disorders Urinary retention	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Reproductive system and breast disorders Vaginal haemorrhage	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Reproductive system and breast disorders Vulvovaginal pruritus	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/3	42.9% 3/7 • Number of events 3	40.0% 2/5 • Number of events 2	42.9% 3/7 • Number of events 3	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/3	42.9% 3/7 • Number of events 4	40.0% 2/5 • Number of events 2	57.1% 4/7 • Number of events 7	33.3% 1/3 • Number of events 1	25.0% 1/4 • Number of events 1	0.00% 0/2	40.0% 2/5 • Number of events 2	40.0% 2/5 • Number of events 2
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	0.00% 0/7	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	20.0% 1/5 • Number of events 1	20.0% 1/5 • Number of events 1
Respiratory, thoracic and mediastinal disorders Hiccups	33.3% 1/3 • Number of events 1	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Respiratory, thoracic and mediastinal disorders Hypoxia	33.3% 1/3 • Number of events 1	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	0.00% 0/5	0.00% 0/5
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Respiratory, thoracic and mediastinal disorders Nasal mucosal discolouration	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/3	28.6% 2/7 • Number of events 2	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Respiratory, thoracic and mediastinal disorders Paranasal sinus hypersecretion	33.3% 1/3 • Number of events 1	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	40.0% 2/5 • Number of events 2	0.00% 0/5
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	0.00% 0/5	0.00% 0/5
Respiratory, thoracic and mediastinal disorders Rhinalgia	0.00% 0/3	14.3% 1/7 • Number of events 1	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Respiratory, thoracic and mediastinal disorders Sinus congestion	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Respiratory, thoracic and mediastinal disorders Wheezing	33.3% 1/3 • Number of events 1	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/3	28.6% 2/7 • Number of events 2	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/3	0.00% 0/7	20.0% 1/5 • Number of events 1	0.00% 0/7	33.3% 1/3 • Number of events 1	25.0% 1/4 • Number of events 1	0.00% 0/2	20.0% 1/5 • Number of events 1	0.00% 0/5
Skin and subcutaneous tissue disorders Hypoaesthesia facial	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 2	0.00% 0/5	0.00% 0/5
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	20.0% 1/5 • Number of events 1	20.0% 1/5 • Number of events 1
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/3	0.00% 0/7	40.0% 2/5 • Number of events 2	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	0.00% 0/5	0.00% 0/5
Skin and subcutaneous tissue disorders Rash	33.3% 1/3 • Number of events 2	57.1% 4/7 • Number of events 4	20.0% 1/5 • Number of events 1	28.6% 2/7 • Number of events 2	0.00% 0/3	0.00% 0/4	50.0% 1/2 • Number of events 1	0.00% 0/5	0.00% 0/5
Skin and subcutaneous tissue disorders Rash erythematous	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 2	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Skin and subcutaneous tissue disorders Rash pruritic	33.3% 1/3 • Number of events 1	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Skin and subcutaneous tissue disorders Skin disorder	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	33.3% 1/3 • Number of events 1	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5
Surgical and medical procedures Frontal sinus operation	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	20.0% 1/5 • Number of events 1
Vascular disorders Flushing	0.00% 0/3	0.00% 0/7	0.00% 0/5	0.00% 0/7	0.00% 0/3	0.00% 0/4	0.00% 0/2	40.0% 2/5 • Number of events 2	0.00% 0/5
Vascular disorders Hypertension	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	33.3% 1/3 • Number of events 1	25.0% 1/4 • Number of events 1	0.00% 0/2	20.0% 1/5 • Number of events 1	0.00% 0/5
Vascular disorders Hypotension	0.00% 0/3	0.00% 0/7	0.00% 0/5	14.3% 1/7 • Number of events 1	0.00% 0/3	0.00% 0/4	0.00% 0/2	0.00% 0/5	0.00% 0/5

Additional Information

Chief Medical Officer

Eli Lilly and Company

Phone: 800-545-5979

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: GT60